title: Myoinositol incorporation into lymphocytes of chronic renal failure patients is impaired.
abstract: Incorporation of myo-[2-3H]-inositol into peripheral blood mononuclear cells (PBMNC) and T-cell enriched lymphocytes was evaluated in in-vitro experiments in chronic renal failure (CRF) patients and healthy subjects. Incorporation of myo-[2-3H]-inositol into the cells of CRF patients on conservative and haemodialysis treatment was found to be impaired in comparison with that observed in normal cells. Following PHA stimulation of the cells of CRF patients myo-[2-3H]-inositol incorporation decreased even further, while it increased in normal cells. Five-hour haemodialysis session significantly depressed myoinositol incorporation into PBMNC, while its incorporation into T-cell enriched lymphocytes remained unaffected. Myoinositol incorporation into PBMNC and T-cell enriched lymphocytes was inhibited by prostaglandins and leukotrienes and was inversely related to the extent of pertussis toxinsensitive G protein activation. Reduced myoinositol incorporation into uraemic PHA-stimulated PBMNC may depend at least in part on their enhanced PGE2 and LTB4 release accompanied by increased intracellular cAMP production. In CRF impaired myoinositol incorporation into immune cells may prove the disarrangement in the early events of transmembrane signal transduction, which may share the responsibility for the cell-mediated immune defect in these patients.
authors.affiliation: 2nd Department of Internal Medicine, WAM, Lódź, Poland.
authors.forename: P
authors.initials: P
authors.lastname: Bartnicki
authors.forename: M
authors.initials: M
authors.lastname: Luciak
authors.forename: Z
authors.initials: Z
authors.lastname: Zbróg
authors.forename: H
authors.initials: H
authors.lastname: Tchórzewski
mesh_terms: D000328:Adult; D000535:Aluminum / Q000494:pharmacology; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000378:metabolism; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D015232:Dinoprostone / Q000378:metabolism; D005260:Female; D005461:Fluorine / Q000494:pharmacology; D006801:Humans; D007294:Inositol / Q000097:blood*; D007424:Intracellular Fluid / Q000187:drug effects / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy; D007975:Leukotriene B4 / Q000378:metabolism; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D008297:Male; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism*; D010835:Phytohemagglutinins / Q000494:pharmacology; D006435:Renal Dialysis; D013601:T-Lymphocytes / Q000187:drug effects / Q000378:metabolism*
chemical_list: D016861:Cyclooxygenase Inhibitors; D016859:Lipoxygenase Inhibitors; D010835:Phytohemagglutinins; C028784:phytohemagglutinin-P; D007975:Leukotriene B4; C053629:fluoroaluminum; D005461:Fluorine; D007294:Inositol; D000535:Aluminum; D000242:Cyclic AMP; D015232:Dinoprostone